AVR 0.22% $18.35 anteris technologies ltd

VascuCel, page-2

  1. 3,092 Posts.
    lightbulb Created with Sketch. 69
    Great post Eire2011, that is some shocking data for Baxter's vascular patch.

    Baxter is a major player in the field of vascular surgery so if these problems result in Baxters pulling their patch from the market (or surgeons shunning it for safety reasons) this would represent a golden opportunity for us.

    I am predicting a very strong launch for VascuCel as vascular surgeons seek to rid themselves of using glutaraldehyde treated patches and all the problems these patches ensue.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.